Invivyd, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Invivyd, Inc. on February 24, 2025, covering events occurring on February 21, 2025, and February 24, 2025. The Company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Global Market under the symbol IVVD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and corporate events rather than financial performance data.
Material Changes and Events
- Nasdaq Compliance Regained: On February 21, 2025, the Company received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement (Listing Rule 5450(a)(1)). The stock had previously fallen below the $1.00 minimum for 30 consecutive business days as of December 27, 2024. Compliance was achieved by maintaining a closing bid price of at least $1.00 for ten consecutive business days.
- FDA Decision on PEMGARDA: On February 24, 2025, the Company issued a press release stating that the FDA declined its request to expand the existing Emergency Use Authorization (EUA) for PEMGARDA (pemivibart) to include the treatment of mild-to-moderate COVID-19 in immunocompromised persons with no alternative therapeutic options.
- Existing EUA Status: The FDA decision resulted in no change to the existing EUA for PEMGARDA regarding pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future outlook. The primary risk highlighted is the regulatory outcome regarding the expansion of the PEMGARDA EUA, which was denied. The risk of delisting due to minimum bid price non-compliance has been resolved as of the report date.
Key Facts for Investor Verification
- Verify the current trading price of IVVD to ensure continued compliance with Nasdaq's $1.00 minimum bid price requirement.
- Review the full text of the February 24, 2025 press release (Exhibit 99.1) for details on the FDA's rationale for declining the EUA expansion.
- Confirm the status of the existing PEMGARDA EUA for pre-exposure prophylaxis remains active and unchanged.
- Monitor future filings for any impact of the FDA decision on the Company's commercial strategy or financial projections.